Business
Cell MedX Corp. Assigned Legal Entity Identifier Number
Cell MedX Corp. Assigned Legal Entity Identifier Number.
About this update from Stimcell Energetics Inc.
[{"type":"text","content":"Cell MedX Corp. (OTCQB: CMXC, 9CX:MUN), (“Cell MedX” or the “Company”), announces that it has been assigned a Legal Entity Identifier number 967600RJ7LKTH79OWE67.About the Legal Entity Identifier Number (“LEI”)The European Union has adopted regulations that require use of the LEI as a barcode equivalent aimed at pinpointing systemic risks. The LEI is a 20-digit alphanumeric code that is an internationally standardized and globally valid identifier for financial market participants. Its purpose is to clearly and unequivocally identify contracting parties, such as other companies, banks and investment funds. It is used to comply with a variety of financial reporting requirements in Europe, including trading, clearing, settlement, custody, collateral and liquidity management, market data and indices. The Deutsche Bӧrse Group has stated that \"the LEI will clearly assist the regulatory authorities in monitoring and analyzing threats to the stability of the financial markets and it can also be utilized by counterparties for risk management purposes\".(See http://deutsche-boerse.com/dbg-en/regulation/regulatorytopics/legal-entity-identifier).Cell MedX meets the requirement that all companies on German Stock Exchanges have an LEI number by January 3, 2018. The Company is listed on the Munich Stock Exchange under the symbol 9CX.Dr. Terrance Owen, CEO, stated, “Adhering to the requirements of the stock exchanges in Germany is important to Cell MedX in order to provide liquidity for European shareholders, especially as we introduce eBalance technology and become better known in the investment community”. About Cell MedX Corp. Cell MedX Corp. is an early development stage bio-tech company focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness and alleviate complications associated with medical conditions including, but not limited to, diabetes and high blood pressure. For more information about the Company and its technology please visit our website at: www.cellmedx.com.On behalf of the Board of Directors of Cell MedX Corp.Terrance OwenCEO & Director Forward Looking StatementsThe information included in this press release has not been reviewed by the FDA or Health Canada, nor has it been peer reviewed. This press release contains forward-looki...